Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$2.41
$0.02(0.79%)
At close: 4:00 PM EDT
$2.41
$0.02(0.79%)
Day’s Range― - ―
52-Week Range$2.20 - $6.52
Previous CloseN/A
Volume9.26K
Average Volume (3M)110.32K
Market Cap
$19.98M
Enterprise Value$5.85
Total Cash (Recent Filing)$8.35M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 13, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume120,337
30 Day Avg. Volume110,319
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.50Price Target Upside377.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase IIb EfficacyRobust 12-month CLOVER WaM results (high ORR/MRR, long DOR and PFS, responses >36 months in >30% of responders) provide durable clinical proof-of-concept. Such efficacy materially strengthens regulatory and commercial prospects in WM and lowers clinical development risk heading into a pivotal trial.
Clear Regulatory Pathway & Breakthrough StatusA defined plan to seek accelerated approval plus Breakthrough designation creates a durable development and regulatory framework. It improves likelihood of priority interactions with FDA, shortens potential time-to-decision, and aligns Phase III design to regulatory expectations—reducing execution uncertainty long-term.
Material Financing To Fund Late-stage WorkThe $35M upfront and up-to-$140M financing structure materially extends runway to support Phase III initiation and potential commercialization planning. While some tranches are milestone-tied, the transaction reduces immediate liquidity pressure and enables sustained investment in clinical execution and regulatory activities.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow indicates the business continues to consume cash from operations. Even with improvement versus 2024, ongoing burn requires repeated financing and constrains strategic flexibility, increasing the probability of dilution or capital-raising distraction over the medium term.
Milestone‑contingent Financing RiskA large portion of available funding depends on clinical, regulatory and market-performance triggers. This structure creates execution and market dependency for essential capital, meaning failed triggers or unfavorable market conditions could produce funding shortfalls and disrupt planned Phase III timing and commercialization preparations.
Pre-revenue And Persistent Net LossesThe company remains pre-revenue with sustained net losses, leaving no operating cash base to fund growth. Long-term sustainability depends entirely on clinical success and external financing; absent commercial revenue, profitability and balance-sheet durability are contingent on achieving regulatory milestones and market uptake.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences Inc’s price range in the past 12 months?
Cellectar Biosciences Inc lowest stock price was $2.20 and its highest was $6.52 in the past 12 months.
What is Cellectar Biosciences Inc’s market cap?
Cellectar Biosciences Inc’s market cap is $19.98M.
When is Cellectar Biosciences Inc’s upcoming earnings report date?
Cellectar Biosciences Inc’s upcoming earnings report date is Aug 13, 2026 which is in 13 days.
How were Cellectar Biosciences Inc’s earnings last quarter?
Cellectar Biosciences Inc released its earnings results on May 14, 2026. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.885 by $0.555.
Is Cellectar Biosciences Inc overvalued?
According to Wall Street analysts Cellectar Biosciences Inc’s price is currently Undervalued.
Does Cellectar Biosciences Inc pay dividends?
Cellectar Biosciences Inc does not currently pay dividends.
What is Cellectar Biosciences Inc’s EPS estimate?
Cellectar Biosciences Inc’s EPS estimate is -0.52.
How many shares outstanding does Cellectar Biosciences Inc have?
Cellectar Biosciences Inc has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences Inc’s price movement after its last earnings report?
Cellectar Biosciences Inc reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.885. Following the earnings report the stock price went up 8.844%.
Which hedge fund is a major shareholder of Cellectar Biosciences Inc?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences Inc
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
CLRB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$11.50
▲(377.18% Upside)
Technical Analysis
Ownership Overview
1.15% Insiders
1.38% Mutual Funds
1.56% Other Institutional Investors
91.83% Public Companies and
Individual Investors